Introduction
In the last decades, breast cancer mortality has been declining in Western countries. Much of this decline has been attributed to early detection and to the use of adjuvant systemic therapy [1] . Adjuvant systemic therapy has greatly improved survival in early breast cancer not only in node-positive but also in nodenegative disease [2] . The absolute magnitude of benefit, however, is higher in node-positive as compared to node-negative patients. This progress in adjuvant systemic therapy has led to consensus recommendations proposing adjuvant systemic therapy for virtually all breast cancer patients [3] . Yet, potential adverse effects of adjuvant therapy may affect the quality of life [4, 5] . Thus, the question '… which patients should be treated?' should be modified to its contrary. Nowadays, it seems more appropriate to ask which patients could be spared a potentially toxic adjuvant therapy. As pointed out in the current St. Gallen recommendations, the treatment decisions should be based primarily on the degree of endocrine responsiveness and on HER2 (table 1) . Endocrine treatment is advised in endocrine-responsive patients even with a low risk of disease recurrence. Chemotherapy is the only option in cases that are both endocrine receptor negative and HER2 negative (so-called triple-negative cases). The St. Gallen consensus panel stated that chemotherapy should be given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine-responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. In HER2-negative patients who are highly or incompletely endocrine responsive, chemotherapy should be considered according to the level of risk. Indeed, in order to avoid over-as well as undertreatment, it is still advisable to select the appropriate treatment strategy on the basis of a careful risk assessment for each individual patient. Beyond any doubt, the single most important histopathologic factor for risk stratification in primary breast cancer is nodal status [6] [7] [8] . Due to earlier detection there are considerably more node-negative than node-positive patients diagnosed. More than two thirds of patients with node-negative breast cancer are alive at 10 years even without adjuvant systemic therapies [6, 7] . However, long-term follow-up of patients randomized to tamoxifen in the NSABP B-14 trial showed that the prognosis of estrogen receptor (ER)-positive patients can be remarkably improved by the use of this endocrine therapy [9] . Building on these findings, the NSABP B-20 trial investigated the addition of chemotherapy with cyclophosphamide, methotrexate, fluorouracil (CMF) to tamoxifen in node-negative breast cancer patients and found further improvement in outcome [9] . Even when investigating the effect of adjuvant chemotherapy and/or tamoxifen in node-negative breast cancer patients with a tumor size of 1 cm or less, a Schmidt benefit for the addition of adjuvant therapy was noticed [10] . The recurrence-free survival for ER-positive patients was 86% after surgery alone, 93% when tamoxifen was added and 95% after the addition of tamoxifen and chemotherapy. Survival in the three groups was 90, 92, and 97%, respectively, with a significant difference between the latter two groups. These authors concluded that use of chemotherapy and/or tamoxifen should be considered even for the treatment of women with ER-negative or ER-positive tumors of 1 cm or less and no axillary lymph node metastases. As stated in an accompanying editorial, we need substantially more clinical and translational research to identify strong prognostic factors. It is only through such research that clinicians will be able to reliably distinguish those patients whose prognosis is sufficiently good that they can disregard the risks of treatment for those patients for whom the benefits far outweigh these risks, thus permitting us to apply beneficial but risky adjuvant therapy efficiently [11] . Due to the comparable small benefit of adding chemotherapy to certain subsets of node-negative breast cancer patients with a presumably excellent overall prognosis, one has to carefully weigh risk and benefit of this potentially toxic therapy.
Clinical Prognostic Indicators in Node-Negative Breast Cancer
Even though the premise 'first -select the target' [12] is the current paradigm for selecting adjuvant therapy in breast cancer, assessment of individual risk is of crucial importance when advising patients to undergo adjuvant therapy. Since single traditional prognostic factors alone are not sufficient to allow for proper risk assessment, combinations of several prognostic factors are commonly used for clinical decision making. In Europe, the most commonly used risk classification is the St. Gallen risk category which is updated regularly after each bi-annual St. Gallen consensus meeting. This risk classification applies to node-negative as well as node-positive patients. However, node-positive patients do not meet the criteria for low risk. Node-negative breast cancer patients are allocated according to the latest St. Gallen risk classification [3] as follows: lowrisk group if all of the following features (T1a-c, G I, ER and/or progesterone receptor (PR) expressed (positive), HER2 neither expressed nor amplified (negative), absence of peritumoral vascular invasion, age ≥ 35) are present. If one of the above criteria is not met, patients are considered as intermediate risk (table 2) . In recent years several studies have validated the St. Gallen risk categories. Applying the 1998 risk classification to Japanese patients with node-negative breast cancer allocated only 3% to the minimal-/low-risk group [13] as compared to 10% of the Australian patients [14] . Even though these latter pa- tients had a 10-year distant relapse-free survival of 100%, the authors argued that an algorithm is useless if it spares only a small fraction of node-negative breast cancer patients from chemotherapy. A subsequent analysis of the 2001 St. Gallen classification by the same group of authors classified more patients as low risk with a 10-year distant disease-free survival (DSF) of 97% [15] . Another validation of the 2001 risk classification in a cohort of Spanish patients showed a significant separation between high and low risk, but again classified only 14% as low risk [16] . Similarly, Otsuki and co-workers [17] investigated the 2003 modification of the St. Gallen risk classification and found a statistically significant separation of nodenegative cases between minimal and average risk considering DFS. However, they also noticed that only 17% of patients were classified as minimal risk and should thus have been spared chemotherapy. In Korean patients with node-negative breast cancer, only 4% were assigned to the minimal-risk group when applying the strict St. Gallen criteria of the 2003 consensus [18] . Indeed, despite the high sensitivity to detect high-risk patients, the St. Gallen risk classification is hampered by a comparably low specificity and by the fact that only a minority of node-negative breast cancer patients is allocated to the low-risk group for which chemotherapy can be safely omitted. These 'traditional' prognostic factors are assessed in the webbased tool Adjuvant! online [19] which has over time gained widespread acceptance. This computer-based model uses age of the patient, a comorbidity assumption, tumor size, histological grade, ER status and number of lymph nodes involved for a calculation of relapse and survival at 10 years. Furthermore, it offers the possibility to estimate the potential benefit of a large array of chemotherapy regimens as well as endocrine therapies. This gives the oncologist the possibility to make joint decisions with their patients in each individual set of circumstances and is a step further towards personalized medicine. In spite of the widespread acceptance of Adjuvant! it is surprising that only very few studies have as yet tried to validate this web-based prognostic tool. Olivotto and co-workers [20] stated that Adjuvant! performed reliably in a cohort of 4083 breast cancer patients from British Columbia when adjusting for certain risk factors. Conversely, Buyse and co-workers [21] failed to show a significant association with survival of nodenegative breast cancer patients when applying a predefined cut-off point to separate between low-and high-risk nodenegative breast cancer patients. On the contrary, a 70-gene signature showed a significant association with both distant DSF and overall survival (OS). For time to distant metastases, clinicopathologic risk using Adjuvant! software yielded an unadjusted hazard ratio (HR) = 1.68 (95% confidence interval (CI) = 0.92-3.07). For OS, Adjuvant! yielded an unadjusted HR = 1.67 (95% CI = 0.93-2.98). Specificity for death within 10 years was improved using the gene signature (42%) as compared to Adjuvant! (29%) or to the St. Gallen risk category (10%). We retrospectively compared Adjuvant! with the St. Gallen risk classification and a novel risk algorithm currently being prospectively evaluated in the clinicopathologic arm of the Node-Negative Breast Cancer-3 (NNBC-3) trial in 410 node-negative breast cancer patients without systemic adjuvant therapy [22] . The NNBC-3 algorithm defined high risk by any of the following criteria: (I) age < 35 years, (II) G III, (III) Schmidt eral sites, and they confirmed the strong association of overexpression of uPA and PAI-1 with recurrence and survival during a median follow-up of 79 months. A subset analysis of node-negative, untreated patients also confirmed the potential utility of these markers for identifying a low-risk cohort in this group [28] . Furthermore, data from a prospective randomized trial showed that it is clinically relevant to use uPA/PAI-1 to stratify node-negative patients into a low-risk and a highrisk group [29] . The estimated 3-year recurrence rate for patients with low tumor levels of uPA and PAI-1 was 6.7%. This rate for patients with high tumor levels of uPA and/or PAI-1 was 14.7% (p = 0.006). Furthermore, high-risk patients in the chemotherapy group showed a trend for benefit from chemotherapy, with a 43.8% lower estimated probability of disease recurrence at 3 years than high-risk patients in the observation group (intention-to-treat analysis: relative risk = 0.56; 95% CI = 0.25-1.28). These encouraging results led to the design of the ongoing NNBC-3 trial [30] . This trial uses uPA/PAI-1 for risk stratification of node-negative breast cancer patients and is expected to enroll 5700 patients. Patients with G I breast cancer and G II carcinomas with low uPA/PAI-1 levels are allocated to the low-risk group and will not receive chemotherapy. Patients with either G III carcinomas or G II tumors with high uPA/PAI-1 belong to the highrisk group ( fig. 1) . These patients will be randomized to receive either 6 cycles 5-fluorouracil/epirubicin/cyclophosphamid (FEC) d1 q3w or 3 cycles FEC followed by 3 cycles docetaxel d1 q3w. This trial will withhold adjuvant chemotherapy only from the low-risk node-negative breast cancer patients. Furthermore, it will answer the question whether highrisk node-negative breast cancer patients might benefit from a taxane-containing regimen. 
Multiparameter Gene Expression Analysis in Node-Negative Breast Cancer
The recent advent of gene expression profiling has allowed researchers to venture into the heterogeneous nature of breast cancer. Perou and co-workers [31] described breast cancer subtypes identified after two-dimensional hierarchical clustering, which they called luminal, basal like, normal like and ERBB2 like. These subtypes differed in their clinical outcome and response to chemotherapy [32] [33] [34] . However, the list of genes used to define these subtypes changed often and proliferation genes were largely neglected in the early publications. Furthermore, a simple, reproducible and comprehensible classification algorithm was difficult to deduce. In a more statistically driven case control design, also called supervised analysis, two different groups identified genes differentially expressed in tumors of node-negative and untreated patients who developed a metastasis within 5 years or remained disease free for at least 5 years [35, 36] . The respective classification algorithms outperformed all other conventional prognostic factors and were confirmed in subsequent validation studies [37, 38] . However, since both lists overlapped by only 3 genes, considerable uncertainty about the validity and general applicability of these findings arose in the medical community [39] . Meanwhile, it is becoming increasingly clear that most prognostic and predictive classification algorithms rely predominantly on the measurement of ERα-regulated genes and genes involved in the cell cycle [40] [41] [42] [43] . In particular, tumors scored as ER positive by immunohistochemistry can be subdivided into a good-and a badoutcome group by proliferation-associated genes [44] . Recently, the impact of the immune system on the prognosis of node-negative breast cancer patients became evident. In a meta-analysis, an immune response gene motive has been shown to distinguish between patients with good and bad outcome in ER-negative tumors [45] . In addition, it was found that high expression of lymphocyte-associated genes conferred a good prognosis in node-negative ERBB2-positive breast cancer [46] . In order to systematically evaluate the prognostic impact of the immune system, we performed gene expression profiling in a discovery cohort study of 200 untreated node-negative breast carcinomas [47] . After performing hierarchical cluster analysis, we identified co-regulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B cell and T cell infiltration. We calculated metagenes as surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with principal component analysis. Distinct patterns led to the hypothesis of a prognostic role of the immune system in tumors with high expression of proliferation-associated genes. In multivariate Cox regression analysis, the proliferation metagene showed a significant association with metastasis-free survival of the whole discovery cohort (HR 2.20; 95% CI 1.40-3.46). The B cell metagene showed additional independent prognostic in- Thus, we could demonstrate in three independent cohorts of untreated node-negative breast cancer patients that the humoral immune system plays a pivotal role for metastasis-free survival of carcinomas of the breast. However, albeit scientifically compelling, these novel findings should presently not be used to guide treatment decisions in node-negative breast cancer patients. Currently, there are two ongoing clinical trials utilizing multiparameter gene expression analysis to stratify node-negative breast cancer patients.
Trial Assigning Individualized Options for Treatment: TAILORx
This trial [48] uses the Oncotype DX assay. This reverse transcriptase-polymerase chain reaction (RT-PCR) assay measures the expression of 21 genes in RNA extracted from formalin-fixed paraffin-embedded samples of tissue from primary breast cancer. This test was developed specifically for patients with ER-positive node-negative breast cancer patients treated with adjuvant tamoxifen. The 21-gene validation study included 668 node-negative patients who participated in the NSABP B-14 trial for whom tumor blocks were available [49] . When evaluated as a categoric variable, the proportions of patients categorized as having a recurrence score (RS) defined as low (< 18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , or high (≥ 31) by the RT-PCR assay were 51, 22, and 27%, respectively. The Kaplan-Meier estimates of the rates of distant recurrence at 10 years in the low-, intermediate-, and high-risk groups were 6.8, 14.3, and 30.5%, respectively. The rate in the low-risk group was significantly lower than that in the high-risk group (p < 0.001). In a multivariate Cox model, the RS provided significant predictive power that was independent of age and tumor size (p < 0.001). The RS was also predictive of OS (p < 0.001) and could be used as a continuous function to predict distant recurrence in individual patients. Subsequent studies in patients treated with tamoxifen with or without adjuvant chemotherapy in NSABP trial B-20 indicated that a high RS seemed to predict benefit from adjuvant chemotherapy [50] . [37] . This second set included 61 patients with lymph node-negative disease used in the prior study that established the test. In this validation trial, the estimated HR for distant metastases by signature was 5.1 (p < 0.001) and remained significant when adjusted for lymph node status. Moreover, it was independent of other prognostic factors like age, node status, tumor diameter, grade, vascular invasion or ER status by multivariable Cox regression analysis. In an effort to overcome possible inaccuracies like sample bias or model overfitting in these initial studies, the TRANSBIG research network performed a prospective validation trial in 302 lymph node-negative patients from five European cancer centers [21] . At a median follow-up of 13.6 years, this study found that the 70-gene signature added independent prognostic information to conventional clinicopathologic risk assessment used in clinical practice, such as the Nottingham Prognostic Index, the St. Gallen criteria, and the Adjuvant! software. The MINDACT trial [51] is expected to enroll 6000 node-negative breast cancer patients who will have their risk assessed through both traditional clinicopathologic factors (using Adjuvant!) and the 70-gene profile (MammaPrint). If both methods classify the patient's risk of relapse as low, adjuvant chemotherapy is withheld; if both methods classify the patient's risk of relapse as high then chemotherapy will be proposed. In case these methods give discordant results, the patient will be randomly assigned to follow the clinicopathologic method or the genomic results.
Conclusion
At the present time, treatment decisions for node-negative breast cancer patients are based primarily on clinicopathologic risk assessment, e.g. the St. Gallen risk classification or Adjuvant! online. However, deciding which patient should be treated with chemotherapy is a continuing challenge for clinicians since these 'traditional' risk classifications have a high sensitivity but only a modest specificity and thus lead to potential overtreatment of a considerable number of node-negative breast cancer patients. From the plethora of novel prognostic factors or tumor markers only uPA/PAI-1 and Oncotype DX have received an evidence-based recommendation for use in clinical practice from ASCO. The MammaPrint assay was classified as 'under investigation'. Study participation of node-negative breast cancer patients in either the NNBC-3 trial, the MINDACT trial or TAILORx is strongly encouraged. These studies will hopefully allow us to quantify the risk of progression in the individual patient and tailor treatment accordingly. This should lead to a more personalized treatment recommendation and thus should help to overcome our less than satisfactory 'one size fits all' approach to early breast cancer treatment. Close interdisciplinary collaboration between clinicians and scientists will be essential to achieve this goal.
